

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1. (Canceled).
2. (Previously presented) A composition comprising a peptide having an amino acid sequence as set forth in SEQ ID NO: 24.
3. (Canceled).
4. (Previously presented) The composition of claim 2, further comprising an active agent, wherein said peptide is complexed to said active agent.
5. (Canceled).
6. (Previously presented) The composition of claim 2, further comprising an active particle, wherein said peptide is complexed to said active particle.
7. (Currently amended) A method for enhancing movement of an active agent across a lipid membrane, comprising a the composition of claim 4 ~~complex selected from the group consisting of a MTLP active agent complex and a MTLP active particle complex~~, wherein the peptide ~~MTLP~~ enhances movement of the active agent across the lipid membrane.
8. (Currently amended) A method for enhancing movement of an active particle across a lipid membrane, comprising a the composition of claim 4 ~~MTLP active particle complex~~, wherein the peptide ~~MTLP~~ enhances movement of the active particle across the lipid membrane.
9. (Canceled) ~~A method for identifying a derivative of a MTLP having enhanced ability to transport an active agent across a lipid membrane, wherein the derivative of the MTLP competes~~

~~for transport of fMLP across a membrane selected from the group consisting of a cell membrane, an intracellular membrane, the apical and basal membranes of an epithelial cell layer.~~

10. (Canceled) ~~The membrane of claim 9, wherein the epithelial cell layer is a polarized epithelial cell layer.~~

11. (Currently amended) A method for treating a pathological disorder in an animal, comprising orally administering to the animal in need of such treatment the composition of claim 4 ~~a complex selected from the group consisting of a MTLP active agent complex and a MTLP active particle complex~~, wherein an amount of the active agent effective to treat the pathological disorder is moved across the gastrointestinal epithelium of the animal into the circulation.

12. (Previously presented) A composition according to Claim 4, wherein the active agent is a viral DNA particle.

13. (Currently amended) A composition according to Claim 12, wherein the DNA is ~~in the form of~~ complexed with a membrane translocating peptide (MTLP)-coated liposome.

14. (Previously presented) A pharmaceutical composition comprising a peptide according to Claim 2 and a pharmaceutical carrier.

15. (Previously presented) A pharmaceutical composition according to Claim 14, adapted for oral administration.

16 to 18. (Canceled)

19. (Previously presented) A composition for use in membrane translocation, the composition consisting of an MTLP comprising an amino acid sequence of SEQ ID NO: 24.

20. (Previously presented) A composition of Claim 19, wherein said MTLP is complexed to a liposome.
21. (Previously presented) A pharmaceutical composition comprising a composition according to Claim 19 and a pharmaceutical carrier.
22. (Previously presented) A pharmaceutical composition according to Claim 20, adapted for oral administration.
23. (Currently amended) A composition for use in membrane translocation, the composition comprising a ~~an~~ membrane translocating peptide (MTLP) comprising an amino acid sequence of SEQ ID NO: 24, wherein said MTLP comprises D-isomers of amino acids or is a D form retroinversion of SEQ ID NO:24 retroinverted peptide.
24. (Previously presented) A composition according to Claim 23, wherein said MTLP is complexed to an active agent to be translocated.
25. (Previously presented) A composition according to Claim 23, wherein said MTLP is complexed to an active particle to be translocated.
26. (Previously presented) A composition to Claim 24, wherein said active agent is a viral DNA particle.
27. (Currently amended) A composition according to Claim 26, wherein said DNA is complexed with ~~in the form of~~ a MTLP-coated liposome.
28. (Previously presented) A pharmaceutical composition comprising a composition according to Claim 23 and a pharmaceutical carrier.

29. (Previously presented) A pharmaceutical composition according to Claim 28, adapted for oral administration.

30. (Previously presented) A method of diagnosis of a pathological disorder by oral administration, the method comprising administering an effective amount of the composition according to Claim 23, wherein said active agent is a diagnostic agent.